immunotherapy
-
August 16, 2022
Nanoparticles boost anti-cancer immunity
An ingenious targeted nanoparticle approach developed by Vanderbilt researchers reduced tumor burden in a model of ovarian cancer. -
August 11, 2022
Couple’s gift helps support immunotherapy research
Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies. -
January 14, 2022
Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy
A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors. -
September 10, 2021
Novel immunotherapy shows robust response for multiple myeloma
Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma. -
August 12, 2021
Study identifies biomarker for breast cancer response to immunotherapy
A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. -
August 5, 2021
Clinical trial to test immunotherapy for rectal cancer
A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer. -
July 1, 2021
Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma
A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.